Page 2 - Ajanta Pharma

Ajanta Pharma Q2 net profit dips 7% to Rs 116 crore; stock ends flat

Income from operations rose to Rs 643 crore during the period under review, as compared with Rs 544 crore in the year-ago period

Domestic drug portfolio a key driver of Ajanta Pharma's growth prospects

Industry beating growth along with high US sales are keeping analysts positive on the company's earnings prospects

Share buyback nod fails to lift Ajanta Pharma; falls 7% on weak Q3 results

The stock dipped 7 per cent to Rs 1,016 on BSE after the company's consolidated net profit more-than-halved at Rs 67 crore in Q3FY19, due to lower sales.

Ajanta Pharma: Reduction in Africa biz may offset branded generic sales

The company is bullish about the prospects of its Africa generic business

Ajanta Pharma: Growth driven by India, US markets

Africa business expected to normalise on the back of currency stability

US go-ahead to lift Ajanta Pharma

The Ajanta Pharma stock was up nearly a per cent after the US Federal Drug Administration (FDA) cleared the company's Dahej plant in Gujarat. The company informed the exchanges that the US FDA inspected its formulation facility last week and cleared it without issuing any Form 483 observations. The Dahej plant is one of the relatively newer plants of Ajanta Pharma set up in 2014 to meet its requirements for the US and emerging markets. The approval is critical for the company as the US is its fastest-growing geography. Though, of the overall ~2,000-crore revenue estimated for FY17, the US will account for just 10 per cent or about ~200 crore, it is crucial for driving future growth. Tushar Manudhane of Motilal Oswal Securities believes the company will grow its US business by 46 per cent annually during FY17-20. This is because the company, which has so far filed 32 abbreviated new drug applications (ANDAs), intends to file 12-15 ANDAs annually from FY18. Among the key products are ...

Ajanta Pharma pares early losses post clarification on USFDA import alert

The stock was down 4% at Rs 1,713, recovering 12% from its intra-day's low of Rs 1,527 on the BSE

Ajanta Pharma Q2 net up 26% at Rs 130.66 crore

Shares of the company were trading at Rs 1,967.45 a scrip in afternoon trade on BSE, down 1.33% from previous close

Ajanta Pharma's Guwahati facility to be ready by March 2017

Facility will produce tablets, capsules, creams and ointments and sterile ophthalmic liquids

Ajanta Pharma Q1 net up 39% at Rs 119.55 crore

Shares of the comapny were trading 3.40% up at Rs 1,707.75 ascrip on BSE

Ajanta Pharma launches acid reflux drug in US

Company has launched the product in the US through its wholly-owned subsidiary, Ajanta Pharma USA Inc

Ajanta Pharma shares jump nearly 4% on USFDA nod for drug

The US health regulator, gives final approval for its generic version of acute migraine pain relief drug.

Ajanta Pharma gains on USFDA nod for Almotriptan Malate tablets

The tablets are used for the treatment of acute migraine pain relief